0001493152-21-031872.txt : 20211217 0001493152-21-031872.hdr.sgml : 20211217 20211217164017 ACCESSION NUMBER: 0001493152-21-031872 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20211217 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211217 DATE AS OF CHANGE: 20211217 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pulmatrix, Inc. CENTRAL INDEX KEY: 0001574235 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 461821392 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36199 FILM NUMBER: 211502164 BUSINESS ADDRESS: STREET 1: 99 HAYDEN AVENUE STREET 2: SUITE 390 CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: (781) 357-2333 MAIL ADDRESS: STREET 1: 99 HAYDEN AVENUE STREET 2: SUITE 390 CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: Ruthigen, Inc. DATE OF NAME CHANGE: 20130411 8-K 1 form8-k.htm
0001574235 false 0001574235 2021-12-17 2021-12-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 17, 2021

 

PULMATRIX, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-36199   46-1821392
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

99 Hayden Avenue, Suite 390
Lexington, MA 02421

(Address of principal executive offices) (Zip Code)

 

(781) 357-2333

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☒ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of exchange on which registered
Common Stock, par value $0.0001 per share   PULM   The NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 8.01 Other Events.

 

As previously reported, on December 15, 2021, Pulmatrix, Inc. (“Pulmatrix” or the “Company”) entered into a securities purchase agreement with certain institutional investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in a registered direct offering (the “Offering”) (i) 6,745.0008 shares of the Company’s Series A Convertible Preferred Stock, par value $0.0001 per share (the “Preferred Stock”), and (ii) 5,620,834 warrants (the “Common Warrants”) to purchase an aggregate of 5,620,834 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”). In connection with the Offering and pursuant to an engagement letter entered into on December 3, 2021, by and between the Company and H.C. Wainwright & Co., LLC (the “Placement Agent”), the Company also agreed to grant to the Placement Agent or its designees warrants to purchase up to 730,708 shares of Common Stock at an exercise price of $0.75 per share (the “Placement Agent Warrants”). On December 17, 2021, the Offering closed.

 

The legal opinion of Haynes and Boone, LLP relating to the legality of the issuance and sale of the Preferred Stock, the Common Warrants and the Placement Agent Warrants and the shares issuable upon the conversion or exercise of the Preferred Stock, the Common Warrants and the Placement Agent Warrants, as applicable, is attached as Exhibit 5.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.

 

On December 17, 2021, the Company issued a press release announcing the closing of the Offering. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

The following exhibits are filed herewith:

 

5.1   Opinion of Haynes and Boone, LLP.
23.1   Consent of Haynes and Boone, LLP (included in Exhibit 5.1).
99.1   Press release, dated December 17, 2021.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

Additional Information and Where to Find It

 

The reverse stock split proposal described in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K, will be submitted to Pulmatrix’s stockholders for their consideration. The Company intends to file a proxy statement (the “Proxy Statement”) that will be sent to all holders of record of Pulmatrix’s Common Stock and Preferred Stock in connection with the reverse stock split. This press release does not contain all the information that should be considered concerning the reverse stock split and is not intended to form the basis of any investment decision or any other decision in respect of the reverse stock split. Pulmatrix’s stockholders and other interested persons are advised to read, when available, the preliminary Proxy Statement and the amendments thereto and the definitive Proxy Statement and other documents filed in connection with the reverse stock split, as these materials will contain important information about Pulmatrix and the reverse stock split. When available, the definitive Proxy Statement and other relevant materials for the proposed reverse stock split will be mailed to stockholders of Pulmatrix as of the record date for voting on the reverse stock split. Pulmatrix stockholders will also be able to obtain copies of the preliminary Proxy Statement, the definitive Proxy Statement and other documents filed with the SEC, without charge, once available, at the SEC’s website at www.sec.gov, or by directing a request to Pulmatrix’s corporate secretary at Pulmatrix, Inc., 99 Hayden Avenue, Suite 390, Lexington, Massachusetts 02421; telephone number (781) 357-2333.

 

Participants in Solicitation

 

Pulmatrix and its directors and executive officers may be deemed participants in the solicitation of proxies from Pulmatrix’s stockholders with respect to the proposed reverse stock split. A list of the names of those directors and executive officers and a description of their interests in Pulmatrix is contained in Pulmatrix’s definitive proxy statement for its 2021 Annual Meeting of Stockholders, which was filed with the SEC and is available free of charge at the SEC’s web site at www.sec.gov. To the extent such holdings of Pulmatrix’s securities may have changed since that time, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. Additional information regarding the interests of such participants will be contained in the Proxy Statement for the proposed reverse stock split when available.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  PULMATRIX, INC.
   
Date: December 17, 2021 By: /s/ Teofilo Raad
    Teofilo Raad
    Chief Executive Officer

 

 

 

 EX-5.1 2 ex5-1.htm

 

Exhibit 5.1

 

 

December 15, 2021

 

Pulmatrix, Inc.
99 Hayden Avenue, Suite 390
Lexington, MA 02421

 

Re: Pulmatrix, Inc.
  Registration Statement on Form S-3, Registration No. 333-256502

 

Ladies and Gentlemen:

 

We have acted as counsel for Pulmatrix, Inc., a Delaware corporation (the “Company”), in connection with the filing with the Securities and Exchange Commission (the “Commission”) pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “Act”) of the Company’s prospectus supplement, dated December 15, 2021 ( the “Prospectus Supplement”), forming part of the registration statement on Form S-3 (Registration No. 333-256502), initially filed by the Company with the Commission on May 26, 2021, and declared effective on June 9, 2021 (the “Registration Statement”). The Prospectus Supplement relates to the proposed sale of (i) 6,745.0008 shares (the “Preferred Shares”) of the Company’s Series A Convertible Preferred Stock, par value $0.0001 per share and convertible into an aggregate of 11,241,668 shares of common stock, par value $0.0001 per share (the “Common Stock”) at an initial conversion price of $0.60 per share at any time after the original issuance date (the “Conversion Shares”), (ii) warrants (the “Common Warrants”) to purchase up to 5,620,834 shares of Common Stock with an exercise price of $0.70 per share of Common Stock (the “Warrant Shares”), and (iii) 730,708 warrants (the “Placement Agent Warrants”) to purchase up to an aggregate of 730,708 shares of Common Stock (the “Placement Agent Warrant Shares” and, together with the Preferred Shares, the Conversion Shares, the Common Warrants and the Placement Agent Warrants, collectively, the “Securities”).

 

Certain of the Securities are being sold pursuant a securities purchase agreement, dated December 15, 2021, between the Company and each purchaser named therein (the “Securities Purchase Agreement”).

 

In rendering the opinions expressed herein, we have examined and relied upon the originals, or copies certified or otherwise identified to our satisfaction, of (i) the Company’s Amended and Restated Certificate of Incorporation and the Restated Bylaws, each as amended and/or restated to date (“Company Charter Documents”); (ii) certain resolutions of the Board of Directors of the Company and the Pricing Committee of the Board of Directors of the Company related to the filing of the Prospectus Supplement, the authorization and issuance of the Securities and related matters; (iii) the Registration Statement, including the prospectus, and all exhibits thereto; (iv) the Prospectus Supplement and the prospectus included in the Registration Statement dated June 9, 2021 (the “Base Prospectus” and together with the Prospectus Supplement, the “Prospectus”); (iv) the Securities Purchase Agreement; (v) the Engagement Agreement, dated December 3, 2021, between the Company and H.C. Wainwright & Co., LLC (the “Engagement Agreement”); (v) a specimen of the Company’s Common Stock certificate; (vi) the form of the Common Warrants; (vii) the Certificate of Designation of Preferences, Rights and Limitations of the Series A Convertible Preferred Stock, certified by the Secretary of State of Delaware as of December 15, 2021, as amended by the Certificate of Correction, dated December 16, 2021 (collectively, the “Certificate of Designation”) and (viii) such other corporate records of the Company, as we have deemed necessary or appropriate for the purposes of the opinions hereafter expressed.

 

Haynes and Boone, LLP

 

30 Rockefeller Plaza | 26th Floor | New York, NY 10112

T: 212.659.7300 | haynesboone.com

 

 
Pulmatrix, Inc.
December 15, 2021
Page 2

 

As to questions of fact material to the opinions expressed below, we have, without independent verification of their accuracy, relied to the extent we deem reasonably appropriate upon the representations and warranties of the Company contained in such documents, records, certificates, instruments or representations furnished or made available to us by the Company.

 

In making the foregoing examination, we have assumed (i) the genuineness of all signatures, (ii) the authenticity of all documents submitted to us as originals, (iii) the conformity to original documents of all documents submitted to us as certified or photostatic copies, (iv) that all agreements or instruments we have examined are the valid, binding and enforceable obligations of the parties thereto, and (v) that all factual information on which we have relied was accurate and complete.

 

We have also assumed that, at the time of the issuance of the Securities: (i) the Company will continue to be incorporated and in existence and good standing in its jurisdiction of organization; (ii) the Registration Statement, and any amendments thereto (including post-effective amendments) will have become effective and will have remained effective; (iii) no stop order of the Commission preventing or suspending the use of the Prospectus will have been issued; (iv) the resolutions of the Board of Directors of the Company and the Pricing Committee of the Board of Directors of the Company referred to above will not have been modified or rescinded; (vi) the Company will receive consideration for the issuance of the Securities and that is at least equal to the par value of the Common Stock; (v) the Securities Purchase Agreement will have been duly authorized and validly executed and delivered by the parties thereto and will be enforceable obligations of the parties thereto; (vi) all requirements of the DGCL, the Company Charter Documents will be complied with when the Securities are issued; (vii) all Securities will be issued and sold in compliance with applicable federal and state securities laws and in the manner stated in the Prospectus; and (viii) neither the issuance nor sale of the Securities will result in a violation of any agreement or instrument then binding upon the Company or any order of any court or governmental body having jurisdiction over the Company.

 

 
Pulmatrix, Inc.
December 15, 2021
Page 3

 

Based upon the foregoing and subject to the assumptions and qualifications stated herein, we are of the opinion that:

 

(1) the Preferred Shares, upon payment and delivery in accordance with the Securities Purchase Agreement and the Prospectus, will be validly issued, fully paid and non-assessable;

 

(2) when the Common Warrants have been duly executed by the Company and the Common Warrants have been issued and sold pursuant to the Prospectus, against payment in full of the consideration payable therefor, the Common Warrants will constitute valid and legally binding obligations of the Company;

 

(3) when the Placement Agent Warrants have been duly executed by the Company and the Placement Agent Warrants have been issued pursuant to the Prospectus, the Placement Agent Warrants will constitute valid and legally binding obligations of the Company;

 

(4) the Warrant Shares have been duly authorized and, upon the valid exercise in accordance with the terms of the Common Warrants and payment in full of the consideration payable therefor, the Warrant Shares will be validly issued, fully paid and non-assessable;

(5) the Conversion Shares have been duly authorized and, upon the valid conversion of the Preferred Shares in accordance with the terms of the Certificate of Designation and the Prospectus, the Conversion Shares will be validly issued, fully paid and non-assessable; and

 

(6) the Placement Agent Warrant Shares have been duly authorized and, upon the valid exercise of the Placement Agent Warrants in accordance with the terms of the Placement Agent Warrants and the Prospectus, the Placement Agent Warrant Shares will be validly issued, fully paid and non-assessable.

 

The opinions expressed herein are limited exclusively to the General Corporation Law of the State of Delaware (the “DGCL”) and applicable provisions of the Delaware Constitution and reported judicial decisions interpreting the DGCL and such provisions of the Delaware Constitution and we have not considered, and express no opinion on, any other laws or the laws of any other jurisdiction.

 

We hereby consent to the filing of this opinion with the Commission as Exhibit 5.1 to the Registration Statement and to the reference to our firm under the heading “Legal Matters” in the Prospectus. In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission thereunder.

 

    Very truly yours,
     
    /s/ Haynes and Boone, LLP
    Haynes and Boone, LLP

 

 

 EX-99.1 3 ex99-1.htm

 

Exhibit 99.1

 

Pulmatrix Announces Closing of $6.75 Million Registered Direct Offering

 

LEXINGTON, Mass., December 17, 2021 /PRNewswire/ — Pulmatrix, Inc. (Nasdaq: PULM) (“Pulmatrix” or the “Company”), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced that it has closed its previously announced registered direct offering with certain institutional investors for the issuance and sale of an aggregate of 6,745.008 shares of convertible preferred stock and warrants to purchase up to an aggregate of 5,620,834 shares of common stock for gross proceeds of $6.75 million, prior to deducting placement agent’s fees and other offering expenses. The shares of preferred stock have a stated value of $1,000 per share and are initially convertible into an aggregate of 11,241,668 shares of common stock at a conversion price of $0.60 per share at any time. The warrants have an exercise price of $0.70 per share, will become exercisable six months following the date of issuance, and will expire 5 years following the date of issuance.

 

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

 

The Company currently intends to use the net proceeds from the offering for general corporate and working capital purposes.

 

The Company expects to call a special meeting of stockholders for the approval of a proposal to effect a reverse split of the common stock. The preferred stock has voting rights, with the common stock as a single class, equal to 5,000 votes per share of common stock underlying the preferred stock on the proposal, that, in accordance with Nasdaq listing rules, any votes cast by the preferred stock with respect to the proposal to effect a reverse split of the common stock must be counted by the Company in the same proportion as the aggregate shares of common stock voted on such proposal.

 

The securities described above were offered and sold by Pulmatrix in a registered direct offering pursuant to a “shelf” registration statement on Form S-3 (Registration No. 333-256502), including a base prospectus previously filed with the Securities and Exchange Commission (the “SEC”) on May 26, 2021 and became effective on June 9, 2021. The securities were offered by means of a prospectus supplement and accompanying prospectus, forming part of the registration statement. The prospectus supplement dated December 17, 2021 and the accompanying base prospectus relating to and describing the terms of the registered direct offering were filed with the SEC on December 17, 2021. Electronic copies of the prospectus supplement and the accompanying base prospectus may be obtained on the SEC’s website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com.

 

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

 

About Pulmatrix, Inc.

 

Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology. The Company’s proprietary product pipeline includes treatments for serious lung diseases, such as allergic bronchopulmonary aspergillosis (“ABPA”), COPD, and neurologic disorders such as acute migraine. Pulmatrix’s product candidates are based on iSPERSE™, its proprietary engineered dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.

 

 
 

 

Forward-Looking Statements

 

Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements of historical fact and statements regarding the intended use of proceeds from the registered direct offering and may be identified by words such as “anticipates,” “assumes,” “believes,” “can,” “could,” “estimates,” “expects,” “forecasts,” “guides,” “intends,” “is confident that”, “may,” “plans,” “seeks,” “projects,” “targets,” and “would,” and their opposites and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the use of net proceeds from the registered direct offering; the impact of the novel coronavirus (COVID-19) on the Company’s ongoing and planned clinical trials; the geographic, social and economic impact of COVID-19 on the Company’s ability to conduct its business and raise capital in the future when needed; delays in planned clinical trials; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company’s ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; the ability to secure and enforce legal rights related to the Company’s products, including patent protection; and the outcome of the Company’s dispute with Cipla regarding the continued development of Pulmazole. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Company’s filings with the SEC, including its most recent annual report on Form 10-K, as amended, as may be supplemented or amended by the Company’s Quarterly Reports on Form 10-Q. The Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

 

Additional Information and Where to Find It

 

The reverse stock split proposal described above will be submitted to Pulmatrix’s stockholders for their consideration. The Company intends to file a proxy statement (the “Proxy Statement”) that will be sent to all holders of record of Pulmatrix’s common stock and preferred stock in connection with the reverse stock split. This press release does not contain all the information that should be considered concerning the reverse stock split and is not intended to form the basis of any investment decision or any other decision in respect of the reverse stock split. Pulmatrix’s stockholders and other interested persons are advised to read, when available, the preliminary Proxy Statement and the amendments thereto and the definitive Proxy Statement and other documents filed in connection with the reverse stock split, as these materials will contain important information about Pulmatrix and the reverse stock split. When available, the definitive Proxy Statement and other relevant materials for the proposed reverse stock split will be mailed to stockholders of Pulmatrix as of the record date for voting on the reverse stock split. Pulmatrix stockholders will also be able to obtain copies of the preliminary Proxy Statement, the definitive Proxy Statement and other documents filed with the SEC, without charge, once available, at the SEC’s website at www.sec.gov, or by directing a request to Pulmatrix’s corporate secretary at Pulmatrix, Inc., 99 Hayden Avenue, Suite 390, Lexington, Massachusetts 02421; telephone number (781) 357-2333.

 

Participants in Solicitation

 

Pulmatrix and its directors and executive officers may be deemed participants in the solicitation of proxies from Pulmatrix’s stockholders with respect to the proposed reverse stock split. A list of the names of those directors and executive officers and a description of their interests in Pulmatrix is contained in Pulmatrix’s definitive proxy statement for its 2021 Annual Meeting of Stockholders, which was filed with the SEC and is available free of charge at the SEC’s web site at www.sec.gov. To the extent such holdings of Pulmatrix’s securities may have changed since that time, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. Additional information regarding the interests of such participants will be contained in the Proxy Statement for the proposed reverse stock split when available.

 

Investor Contact:

 

Timothy McCarthy, CFA

212.915.2564

tim@lifesciadvisors.com

 

 

 

 GRAPHIC 4 ex5-1_1.jpg begin 644 ex5-1_1.jpg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

%;CQ=XABT^,M' /GN)@N?+0?U/0>Y MKZJMX([6VBMX5"Q1($11V & *FK+H8XVIHH(DHHHK$\X**** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@"CJ^CV&NZ=)8:C;I/;R?PL.5/8@]B/6OGKQA\+-8\,DW-H M'U&P.&_$4A MEU#2XFG/)GB)CZWXLN 886M;(8WW%-$D6:#2TGG7I+5O4_T':MRBBL M6[G VY.["BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 )44 %%%% '__9 end GRAPHIC 5 ex5-1_2.jpg begin 644 ex5-1_2.jpg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end EX-101.SCH 6 pulm-20211217.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 7 pulm-20211217_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 8 pulm-20211217_pre.xml XBRL PRESENTATION FILE XML 9 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001574235 2021-12-17 2021-12-17 iso4217:USD shares iso4217:USD shares 0001574235 false 8-K 2021-12-17 PULMATRIX, INC. DE 001-36199 46-1821392 99 Hayden Avenue Suite 390 Lexington MA 02421 (781) 357-2333 false true false false Common Stock, par value $0.0001 per share PULM NASDAQ false XML 10 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover
Dec. 17, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 17, 2021
Entity File Number 001-36199
Entity Registrant Name PULMATRIX, INC.
Entity Central Index Key 0001574235
Entity Tax Identification Number 46-1821392
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 99 Hayden Avenue
Entity Address, Address Line Two Suite 390
Entity Address, City or Town Lexington
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02421
City Area Code (781)
Local Phone Number 357-2333
Written Communications false
Soliciting Material true
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol PULM
Security Exchange Name NASDAQ
Entity Emerging Growth Company false

EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://pulmatrix.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex5-1.htm ex99-1.htm pulm-20211217.xsd pulm-20211217_lab.xml pulm-20211217_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "pulm-20211217_lab.xml" ] }, "presentationLink": { "local": [ "pulm-20211217_pre.xml" ] }, "schema": { "local": [ "pulm-20211217.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "PULM", "nsuri": "http://pulmatrix.com/20211217", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2021-12-17to2021-12-17", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://pulmatrix.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2021-12-17to2021-12-17", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://pulmatrix.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 17 0001493152-21-031872-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-21-031872-xbrl.zip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end